The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study

NCT01217476 | Completed Phase 3 Results DMC

• 2 other identifiers: TFM-CL3-0022010-021015-16
• Study Type: interventional
• Target: 207
• Locations: 10 countries
• Sites: 37

Brief Summary

Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan). Trafermin 0.01% cutaneous spray product kit consisting of a glass bottle containing lyophilized trafermin, a glass bottle with solvent for solution and a spray part to fit the glass bottle after reconstitution of the final product. We conduct a multinational, randomized, double-blind, placebo controlled, parallel-group, multicentre study consisting of a placebo run-in phase (2w), a treatment phase (max. 12w) and a follow-up phase (3mo+6mo). The primary objective of the study is to demonstrate a superior wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin after a maximum of 12 weeks topical daily application of trafermin 0.01% spray compared with placebo, in addition to best local care (off-loading, dressings). Approximately 210 patients will be randomized and it is planned that this study will be conducted at approximately 40 investigational sites in Europe.

Conditions

Diabetic Foot Ulcer of Neuropathic Origin

Keywords

Diabetic foot; Neuropathic; Wound; Growth factor

Outcome Measures

Primary Outcomes (1)

• Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition to Best Local Cares

  wound closure is defined as 100% reepithelialization of the target DFU, without exudates.

  12 weeks

Secondary Outcomes (1)

• Relative Wound Area Regression of 40% or More at 6 Week

  6 weeks

Study Arms (2)

Trafermin 0.01% spray

ACTIVE COMPARATOR

Drug: Trafermin 0.01% spray

Matching placebo spray

PLACEBO COMPARATOR

Drug: Trafermin 0.01% spray

Interventions

Trafermin 0.01% spray DRUG

For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface

Matching placebo spray; Trafermin 0.01% spray

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• Provide written informed consent to participate.
• Male or female patients age 18 years or older.
• Type 1 or 2 diabetes.
• A single full-thickness DFU that has been present for at least 2 weeks.
• DFU wound surface area below or equal 34 cm2 on the target foot.
• No exposure of bone in the target DFU.
• Neuropathy confirmed by loss of protective sensation to monofilament test (Semmes-Weinstein 5.07 monofilament).
• No predominant ischemia requiring further exploration or treatment, and confirmed by either:
• ABPI on the target leg (\>0.9; below or equal 1.3) or if ABPI is \>1.3 or is not assessable,TBPI on target foot ³above or equal 0.7, OR
• ABPI on target leg (above or equal 0.7 - below or equal 0.9) or if ABPI is \>1.3 or is not assessable, TBPI on target foot \<0.7, AND a toe blood pressure \>40 mmHg
• Patients who fulfill all of the following criteria are eligible for randomization:
• Completed the 2-week placebo run-in period during which they were compliant to off-loading and to daily application of placebo spray, without major protocol violation. Compliance with the placebo run-in treatment regimen must be "excellent" or "acceptable".
• Glycosylated hemoglobin (HbA1c) below or equal 10% (from a blood sample taken during the placebo run-in period).
• Non-infected target foot DFU of confirmed neuropathic origin with:
• ABPI on the target leg (\>0.9; below or equal 1.3) or if ABPI is \>1.3 or is not assessable, TBPI on target foot above or equal 0.7, OR

Sponsors & Collaborators

• Olympus Biotech Corporation: lead

Study Sites (37)

Unknown Facility

Brussels, 1070, Belgium

Location

Unknown Facility

Liège, 4000, Belgium

Location

Unknown Facility

Rumst, 2840, Belgium

Location

Unknown Facility

Sofia, 1407, Bulgaria

Location

Unknown Facility

Crikvenica, 51 260, Croatia

Location

Unknown Facility

Pula, 52 100, Croatia

Location

Unknown Facility

Zagreb, 10 000, Croatia

Location

Unknown Facility

Aalborg, 9000, Denmark

Location

Unknown Facility

Bad Mergentheim, 97980, Germany

Location

Unknown Facility

Bad Nauheim, 61231, Germany

Location

Unknown Facility

Cologne, 50733, Germany

Location

Unknown Facility

Münster, 48145, Germany

Location

Unknown Facility

Oldenburg, 23758, Germany

Location

Unknown Facility

Trier, 45292, Germany

Location

LL

Budapest, 1036, Hungary

Location

PF

Budapest, 1036, Hungary

Location

Unknown Facility

Hatvan, 3000, Hungary

Location

Unknown Facility

Almelo, 7600, Netherlands

Location

Unknown Facility

Amsterdam, 1105, Netherlands

Location

Unknown Facility

Apeldoorn, 7334, Netherlands

Location

Unknown Facility

Delft, 2625, Netherlands

Location

Unknown Facility

Kalisz, 62 800, Poland

Location

Unknown Facility

Lodz, 90 302, Poland

Location

Unknown Facility

Lodz, 94 238, Poland

Location

Unknown Facility

Lublin, 20090, Poland

Location

Unknown Facility

Poznan, 60111, Poland

Location

Unknown Facility

Szczecin, 70 215, Poland

Location

Unknown Facility

Warsaw, 00 132, Poland

Location

Unknown Facility

Wroclaw, 50403, Poland

Location

Unknown Facility

Wroclaw, 51124, Poland

Location

Unknown Facility

Zielona Góra, 65 945, Poland

Location

Unknown Facility

Dunajská Streda, 929 01, Slovakia

Location

Unknown Facility

L'ubochna, 034 91, Slovakia

Location

Unknown Facility

Nové Zamky, 940 01, Slovakia

Location

Unknown Facility

Vráble, 952 01, Slovakia

Location

EL

Malmo, SE 205 02, Sweden

Location

ML

Malmo, Sweden

Location

MeSH Terms

Conditions

Diabetic Foot; Wounds and Injuries

Interventions

trafermin

Condition Hierarchy (Ancestors)

Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Foot Ulcer; Leg Ulcer; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Diabetic Neuropathies

Results Point of Contact

• Title: Mr. Akira Kondo, Manager, Clinical R&D
• Organization: Olympus France S.A.S

akira.kondo@olympus.fr

+33-1-4560-6849

Study Officials

• Jean-Charles Kerihuel, MD

  VERTICAL

  STUDY DIRECTOR

• Luc Téot, MD

  Montpellier University Hospital

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 7, 2010
• First Posted: October 8, 2010
• Study Start: December 1, 2010
• Primary Completion: May 1, 2012
• Study Completion: March 1, 2013
• Last Updated: August 5, 2014
• Results First Posted: August 5, 2014

Record last verified: 2014-08

Locations

SL (4); DK (1); SE (2); BU (1); PL (10); DE (6); HU (3); BE (3); NL (4); CR (3)